Deferitrin is a novel, orally available iron chelator. Deferitrin may be useful as chelation monotherapy or as part of combination or doublet chelation therapy for the treatment of severe iron overload in patients with beta-thalassemia major if its favorable pharmacokinetic profile, efficacy, safety and tolerability are confirmed in more extensive clinical trials. A phase I/II clinical trial that began in September 2003 has reportedly completed recruitment. Deferitrin was safe, well-tolerated, and well-absorbed either with food and fasting in beta-thalassemia patients. Renal excretion of deferitrin uncomplexed with iron was similar to that seen in preclinical studies, which predict iron excretion to be via the fecal route. Further studies are ongoing to define the effect of deferitrin on iron balance.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Drug evaluation: Deferitrin for iron overload disorders.
Barton JC. IDrugs. 2007 Jul;10(7):480-90. PMID: 17642018.
Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders.
Barton JC. IDrugs. 2007 Apr;10(4):270-81. PMID: 17390251.
Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.
Donovan JM, et al. Ann N Y Acad Sci. 2005;1054:492-4. PMID: 16339704.
|Related 5-HT Receptor Products|
TG6-10-1 is a potent and selective antagonist for the prostaglandin E2 receptor subtype EP2.
WAY-100135 dihydrochloride is a potent, selective 5-HT1A receptor antagonist (IC50 = 15 nM).
|Ziprasidone HCl monohydrate
Ziprasidone(CP88059) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.
Ziprasidone HCl is a novel and potent dopamine and serotonin (5-HT) receptor antagonist, used in the treatment of schizophrenia and bipolar disorder.
Vortioxetine (Lu AA21004) is a multimodal serotonergic agent, inhibits 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7 receptor and SERT with IC50 of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.